Related Experiment Videos

Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside

T Sasaki1, Y Jyo, N Tanda

  • 1Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan.

Kidney International
|January 1, 1997
PubMed

Insights

Fibroblast growth factor 2 (FGF2) exacerbates kidney injury in PAN nephropathy rats by increasing proteinuria and podocyte damage. Neutralizing FGF2 shows therapeutic potential, reducing lesions and improving kidney function.

Area of Science:

  • Nephrology
  • Cell Biology
  • Biochemistry

Background:

  • Podocyte injury is a key feature of nephropathy.
  • Fibroblast growth factor 2 (FGF2) role in kidney disease is not fully understood.

Purpose of the Study:

  • To investigate the role of FGF2 in podocyte damage and glomerulosclerosis in PAN nephropathy rats.
  • To evaluate the therapeutic potential of FGF2 neutralization.

Main Methods:

  • PAN nephropathy induced in rats.
  • Administration of FGF2 or FGF2 neutralizing antibody.
  • Assessment of proteinuria, cell proliferation (PCNA), and podocyte injury marker (desmin).

Main Results:

  • FGF2 administration increased urinary protein and glomerular cell proliferation.
  • FGF2 neutralizing antibody reduced proteinuria, cell proliferation, and podocyte injury.
  • FGF2 promoted the formation of glomerular adhesive lesions.

Conclusions:

  • FGF2 exacerbates PAN nephropathy by stimulating podocyte proliferation and directly impairing podocytes.
  • FGF2 neutralization is a promising therapeutic strategy for treating podocyte injury in nephropathy.

Related Concept Videos